Quality of life assessment in patients with moderate to severe allergic rhinitis treated with montelukast and/or intranasal steroids: A randomised, double-blind, placebo-controlled study

Journal of Laryngology and Otology

Volumn 128, Issue 3, 2014, Pages 242-248

  Goh, B S ^a,b   Ismail, M I M ^c   Husain, S ^a  

^a UNIVERSITI KEBANGSAAN MALAYSIA MEDICAL CENTER   (Malaysia)

^b UNIVERSITI KEBANGSAAN MALAYSIA   (Malaysia)

^c Hospital Melaka   (Malaysia)

Author keywords

Allergic Rhinitis; Fluticasone Propionate; Montelukast; Quality Of Life

Indexed keywords

FLUTICASONE PROPIONATE; LORATADINE; MONTELUKAST; PLACEBO; ACETIC ACID DERIVATIVE; ANDROSTANE DERIVATIVE; ANTIALLERGIC AGENT; FLUTICASONE; GLUCOCORTICOID; HISTAMINE H1 RECEPTOR ANTAGONIST; LEUKOTRIENE RECEPTOR BLOCKING AGENT; QUINOLINE DERIVATIVE;

ADOLESCENT; ADULT; ALLERGIC RHINITIS; ARTICLE; ASSESSMENT OF HUMANS; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PROSPECTIVE STUDY; QUALITY OF LIFE ASSESSMENT; RANDOMIZED CONTROLLED TRIAL; RHINOCONJUNCTIVITIS QUALITY OF LIFE QUESTIONNAIRE; TABLET; TREATMENT DURATION; DRUG COMBINATION; FOLLOW UP; INTRANASAL DRUG ADMINISTRATION; MIDDLE AGED; OUTCOME ASSESSMENT; QUALITY OF LIFE; QUESTIONNAIRE; RHINITIS, ALLERGIC, SEASONAL; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

ACETATES; ADMINISTRATION, INTRANASAL; ADOLESCENT; ADULT; ANDROSTADIENES; ANTI-ALLERGIC AGENTS; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; GLUCOCORTICOIDS; HISTAMINE H1 ANTAGONISTS, NON-SEDATING; HUMANS; LEUKOTRIENE ANTAGONISTS; MALE; MIDDLE AGED; OUTCOME ASSESSMENT (HEALTH CARE); PROSPECTIVE STUDIES; QUALITY OF LIFE; QUESTIONNAIRES; QUINOLINES; RHINITIS, ALLERGIC, SEASONAL; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 84922017358     PISSN: 00222151     EISSN: 17485460     Source Type: Journal    
DOI: 10.1017/S002221511400036X     Document Type: Article

References (13)

1. Bousquet J, van Cauwenberge P, Khaltaev N; Aria Workshop Group, World Health Organization. Allergic rhinitis and its impact on asthma. J Allergy Clin Immunol 2001;108:S147-334
2. Linneberg A, Nielsen NH, Madsen F, Frølund L, Dirksen A, Jørgensen T. Increasing prevalence of specific IgE to aeroallergens in an adult population: two cross-sectional surveys 8 years apart: the Copenhagen Allergy Study. J Allergy Clin Immunol 2000;106:247-52
3. Blaiss MS. Cognitive, social, and economic costs of allergic rhinitis. Allergy Asthma Proc 2000;21:7-13
4. Crystal-Peters J, Crown WH, Goetzel RZ, Schutt DC. The cost of productivity losses associated with allergic rhinitis. Am J Manag Care 2000;6:373-8
5. Kremer B, den Hartog HM, Jolles J. Relationship between allergic rhinitis, disturbed cognitive function and psychological wellbeing. Clin Exp Allergy 2002;32:1310-15
6. Bousquet J, van Cauwenberge P, Khaltaev N and the workshop expert panel. Allergic rhinitis and its impact on astma (ARIA), in collaboration with the World Health Organization. Executive summary of the workshop report. Allergy 2002;57:841-55
7. Okuda M, Watase T, Mezawa A, Liu CM. The role of leukotriene D4 in allergic rhinitis. Ann Allergy 1988;60:537-40
8. StormsW, Michel TM, Knorr B, Noonan G, Shapiro G, Zhang J et al. Clinical safety and tolerability of montelukast, a leukotriene receptor antagonist, in controlled clinical trials in patients aged >or =6 years. Clin Exp Allergy 2001;31:77-87
9. Nayak AS, Philip G, Lu S, Malice MP, Reiss TF. Efficacy and tolerability of montelukast alone or in combination with loratadine in seasonal allergic rhinitis: a multicenter, randomized, double-blind, placebo-controlled trial performed in the fall. Ann Allergy Asthma Immunol 2002;88:592-600
10. Van Adelsberg J, Philip G, LaForce CF, Weinstein SF, Menten J, Malice MP et al. Randomized controlled trial evaluating the clinical benefit of montelukast for treating spring seasonal allergic rhinitis. Ann Allergy Asthma Immunol 2003;90:214-22
11. Patel P, Philip G, Yang W, Call R, Horak F, LaForce C et al. Randomized, double-blind, placebo-controlled study of montelukast for treating perennial allergic rhinitis. Ann Allergy Asthma Immunol 2005;95:551-7
12. Juniper EF, Thompson AK, Ferrie PJ, Roberts JN. Development and validation of the mini Rhinoconjunctivitis Quality of Life Questionnaire. Clin Exp Allergy 2000;30:132-40
13. Virchow JC, Bachert C. Efficacy and safety of montelukast in adults with asthma and allergic rhinitis. Respir Med 2006;100: 1952-9